Varela-M, Rubén E <br/><br/>
The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine.  [electronic resource] 

 -  Acta tropica  Mar 2014 
 - 32-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-6254 
<br/><br/><label>Standard No.: </label>10.1016/j.actatropica.2013.11.018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Benzoquinones--pharmacology<br/>Culture Media<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>Drug Therapy, Combination<br/>G1 Phase Cell Cycle Checkpoints--drug effects<br/>Gene Expression<br/>HSP90 Heat-Shock Proteins--antagonists & inhibitors<br/>Lactams, Macrocyclic--pharmacology<br/>Leishmania--drug effects<br/>Leishmania infantum--drug effects<br/>Phospholipid Ethers--pharmacology<br/>Protozoan Proteins--antagonists & inhibitors<br/>Resting Phase, Cell Cycle--drug effects